Supernus Reaffirms Outlook as Annual Growth Accelerates
First-quarter revenue totaled $207.7 million, easing from the preceding three months.
The central nervous system drug maker Supernus Pharmaceuticals (SUPN) reported 39% revenue growth for the first quarter, accelerating from 21% in the prior quarter despite a sequential decline.
The quarter extended Supernus’s rapid year-over-year expansion while showing softer sales from the fourth quarter. Combined revenue from its four growth products fell to $149.1 million from $161.3 million sequentially, though annual growth accelerated to 56% from 45%.
Total revenue declined from $211.6 million in the fourth quarter. The company reiterated its full-year outlook, which calls for revenue of $840 million to $870 million, operating earnings of zero to $30 million, and adjusted operating earnings of $140 million to $170 million.
Qelbree remained the largest growth product, with sales declining sequentially to $77.9 million from $81.0 million. Sales rose 20% from a year earlier, accelerating from 9% growth in the fourth quarter, while prescriptions edged higher to 254,824.
GOCOVRI followed a similar trajectory. Sales fell to $35.2 million from $38.6 million sequentially, while year-over-year growth accelerated to 15% from 5%. ZURZUVAE collaboration revenue declined to $27.6 million from $32.8 million, and U.S. sales growth moderated to about 100% from about 187%.
ONAPGO net product sales slipped to $8.4 million from $8.9 million even after new-patient initiation resumed in February. Enrollment continued to expand, reaching about 2,200 submitted forms from more than 645 prescribers through April, up from more than 1,800 forms and over 540 prescribers previously reported since launch.
Supernus expects to submit an ONAPGO second supplier for Food and Drug Administration review in the third quarter of 2026, with potential approval by mid-2027. The timetable added detail to its earlier expectation that the supplier would begin providing product in 2027, making that regulatory process a key constraint on the treatment’s expansion.